James Bowman

[James Bowman @binder_finder_]

Excited to share that a de novo designed miniprotein that myself, @bahl_lab, and @frankteets created during my post-doc is now in humans! The miniprotein is a Nectin-4 binding radiopharmaceutical being developed by Aktis Oncology.

[James Bowman @binder_finder_]

This approach is awesome! We’ve used it to purify tens of thousands of de novo proteins without modifying the method for differences in fold, size, or surface properties. Even better, each prep yields enough material for a full battery of characterization assays.

[chris bahl @bahl_lab]

Every protein designer knows that producing & testing designed proteins is a foundational capability for our field, & this is still pretty challenging for a lot of folks. This is why I'm delighted to share our work to make high-throughput protein production more accessible.

🧵👇

[chris bahl @bahl_lab]

Every protein designer knows that producing & testing designed proteins is a foundational capability for our field, & this is still pretty challenging for a lot of folks. This is why I'm delighted to share our work to make high-throughput protein production more accessible.

🧵👇

[Boston Protein Design and Modeling Club @ProteinBoston]

If you missed @jamesproney's stellar talk last night, have no fear because you can check out the recording 👇
https://t.co/oZhZTHnwRr

[AI Proteins @AI_Proteins]

Three weeks ago, we welcomed the local scientific community to join us at our headquarters in Kenmore Square for the inaugural lecture in the AI Proteins Seminar Series. Our speaker Neil King from @UWproteindesign delivered a superb seminar. Check it out👇 https://t.co/XdBcgtRcfm

[Ben Fry @benf549]

My first-author paper describing our protocol for the zero-shot de novo design of drug-binding proteins is now available as an article in Nature! Here’s what we did and what's new from the preprint posted last year 🧵 (1/10):

[AI Proteins @AI_Proteins]

We're delighted to kick off our new seminar series, and the inaugural speaker is none other than Neil King @KingLabIPD

"ML-based design of nanoparticle vaccines"
June 3rd 2026
12-1 PM EDT

[Yehlin Cho @ChoYehlin]

We measured stability for 1.8M diverse protein domains (60–80 aa) from the MGnify metagenomic database, spanning 200k+ sequence families, and created the MGnify Stability Dataset.

[chris bahl @bahl_lab]

As someone who had a career in academia before industry - there are many things I love about academia, but my job satisfaction is higher in industry

I hope things get better for all my friends in academia, because switching isn't the solution for everyone
https://t.co/rojB8Aql9U

[Martin Pacesa @MartinPacesa]

Here are the success rates of de novo pipelines based on which designs I could actually identify the methods for.

[Diego del Alamo @DdelAlamo]

Glycine/serine-rich CDRs are the em dash of structure-based antibody language models

[AI Proteins @AI_Proteins]

AI Proteins has closed a $41.5 million Series A financing to accelerate the development of de novo #miniproteins! The round was led by @MissionBioCap and SANTÉ, with robust participation from existing investors.

See the official press release for details: https://t.co/cHH7QuLIBJ

[chris bahl @bahl_lab]

The next chapter for @AI_Proteins is officially underway! I'm absolutely delighted to share that we’ve closed a $41.5M Series A led by @MissionBioCap and Santé Ventures

https://t.co/6qPM8BvCoY

[James Bowman @binder_finder_]

But creating new ones, molecules nature never evolved, required going beyond binder design to reimagining how we optimize, express, and characterize miniproteins at scale. With the platform we’ve built, we’re excited to continue moving miniprotein medicines closer to patients.

[James Bowman @binder_finder_]

I’m thrilled to share the announcement of AI Proteins' $41.5M Series A, led by Mission BioCapital and SANTÉ. Miniproteins have shown enormous therapeutic promise (insulin being the classic example). https://t.co/grQIaQwjau

[Andrew Dunn @AndrewE_Dunn]

“I don’t think the world needs another antibody company,” AI Proteins CEO Chris Bahl told me. “There’s plenty of those.”

So Bahl built a miniproteins company, instead, now raising a $41.5M Series A.

Will start spinning assets out into standalone LLCs:
https://t.co/qsa9bGTLOp

[chris bahl @bahl_lab]

My new @TEDTalks from the main stage just went live!

https://t.co/sJC0AssBG1

🧵👇

[AI Proteins @AI_Proteins]

Congratulations to Dr. James Bowman @binder_finder_ on his promotion to Chief Technology Officer!

https://t.co/SY1MjEBpAV

[Martin Pacesa @MartinPacesa]

Exciting to see our protein binder design pipeline BindCraft published in its final form in @Nature ! This has been an amazing collaborative effort with Lennart, @csche11h, @sokrypton, @befcorreia and many other amazing lab members and collaborators.

https://t.co/PTMoqQqwcU

[James Bowman @binder_finder_]

As CTO, I am excited to lead the incredibly talented and hardworking team who built our platform and who make it possible to generate transformative miniprotein based medicines for patients.

[James Bowman @binder_finder_]

I am incredibly grateful for the opportunity to serve as the CTO at @AI_Proteins . I’m the first person in this role at the company, and it demonstrates our commitment to continue industrializing the process of miniprotein engineering.
🧵

[James Bowman @binder_finder_]

every step has been rebuilt, optimized, or replaced—a reflection of our relentless commitment to rethinking how proteins are designed and developed